Novartis Reports Results of Xolair (omalizumab) in Two P-III Studies for Chronic Rhinosinusitis with Nasal Polyps in Adults

Shots:

• The P-III POLYP 1 & POLYP 2 studies results involve assessing of Xolair (SC, q2w/q4w) vs PBO in 138 & 127 patients with CRSwNP with inadequate response to intranasal corticosteroids respectively
• The P-III POLYP 1 & POLYP 2 studies resulted in meeting its 1EPs & 2EPs, i.e, change in Nasal Polyp Score (NPS) & Nasal Congestion Score (NCS) @24wks. and is well tolerated
• Xolair is a biologic targeting IgE resulted in reducing the amount of free IgE and is approved in 90+ countries including the US & EU for moderate-to-severe or severe persistent allergic asthma, jointly developed & promoted by Novartis & Genentech in the US

Click here to read full press release/ article | Ref: Novartis | Image: Pharmafile